Quantcast

Latest MB07803 Stories

2008-11-03 09:00:07

Metabasis Therapeutics (Nasdaq: MBRX) announced today that an oral presentation summarizing the results from the Company's Phase 2a clinical trial for MB07803 was given at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), in Barcelona, Spain.

2008-09-23 18:00:37

Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that it has initiated a clinical trial to evaluate higher doses of MB07803 in patients. MB07803 is Metabasis' second-generation FBPase inhibitor product candidate for the treatment of type 2 diabetes.

2008-07-29 18:00:20

Metabasis Therapeutics (Nasdaq: MBRX) announced today that an oral presentation summarizing the results from the Company's Phase 2a clinical trial for MB07803 will be given at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), to be held in Barcelona, Spain, October 30 to November 2, 2008.


Word of the Day
bretelles
  • In dressmaking, straps running from the belt in front over the shoulders to the belt in the back, with more or less elaboration of trimming and outline. They usually broaden at the shoulder and narrow toward the waist.
The word 'bretelles' comes from a French word meaning 'braces'.